AR077892A1 - Quinolinas antagonistas de la hepcidina - Google Patents
Quinolinas antagonistas de la hepcidinaInfo
- Publication number
- AR077892A1 AR077892A1 ARP100103045A ARP100103045A AR077892A1 AR 077892 A1 AR077892 A1 AR 077892A1 AR P100103045 A ARP100103045 A AR P100103045A AR P100103045 A ARP100103045 A AR P100103045A AR 077892 A1 AR077892 A1 AR 077892A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- hydrogen
- group
- alkynyl
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/32—Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Composiciones farmacéuticas que las comprenden y su uso como medicamentos, en particular para el tratamiento de desordenes del metabolismo del hierro, particularmente enfermedades de deficiencia del hierro y anemias, particularmente anemias en conexion con enfermedades inflamatorias cronicas. Reivindicacion 1: Compuestos de la formula general (1) caracterizados porque R1, R2 y R7 son iguales o distintos entre sí y cada uno de ellos está elegido del grupo que comprende: hidrogeno, hidroxilo, halogeno, ciano, nitro, carboxilo, el radical de ácido sulfonico (-SO3H), aminocarbonilo opcionalmente sustituido, aminosulfonilo opcionalmente sustituido, amino opcionalmente sustituido, alquilo opcionalmente sustituido, acilo opcionalmente sustituido, alcoxicarbonilo opcionalmente sustituido, aciloxi opcionalmente sustituido, alcoxi opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido; R6 está elegido en el grupo que comprende: hidrogeno, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido; R3 está elegido del grupo que comprende: hidrogeno, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, acilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido; y R4 y R5 pueden ser iguales o distintos entre si y cada uno de ellos esta elegido del grupo que comprende: hidrogeno, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, acilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido; o en donde R4 y R5 conjuntamente con el átomo de nitrogeno al cual están ligados forman un ciclo saturado o insaturado opcionalmente sustituido de 5 a 8 miembros que puede opcionalmente contener otros hetero-átomos; o sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09168255 | 2009-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR077892A1 true AR077892A1 (es) | 2011-09-28 |
Family
ID=41395069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100103045A AR077892A1 (es) | 2009-08-20 | 2010-08-19 | Quinolinas antagonistas de la hepcidina |
Country Status (8)
Country | Link |
---|---|
US (1) | US20120196853A1 (es) |
EP (1) | EP2467361A1 (es) |
JP (1) | JP2013502399A (es) |
CN (1) | CN102574805A (es) |
AR (1) | AR077892A1 (es) |
BR (1) | BR112012003701A2 (es) |
TW (1) | TW201109324A (es) |
WO (1) | WO2011020886A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8658170B2 (en) | 2010-01-06 | 2014-02-25 | Joseph P. Errico | Combination therapy with MDM2 and EFGR inhibitors |
EP2521551A4 (en) * | 2010-01-06 | 2013-08-21 | Errico Joseph P | METHOD AND COMPOSITIONS FOR TARGETED ACTIVE DEVELOPMENT |
US20150150869A1 (en) * | 2012-06-20 | 2015-06-04 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
WO2014081953A1 (en) * | 2012-11-21 | 2014-05-30 | Richard David J | Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives |
AP2015008502A0 (en) * | 2012-12-24 | 2015-06-30 | Cadila Healthcare Ltd | Novel quinolone derivatives |
US10732182B2 (en) | 2013-08-01 | 2020-08-04 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
JP6538044B2 (ja) | 2013-10-30 | 2019-07-03 | ユートロピクス ファーマシューティカルズ, インコーポレイテッド | 化学療法感受性および化学毒性を判定する方法 |
HUP1500098A2 (hu) * | 2015-03-09 | 2016-09-28 | Avidin Kft | 8-hidroxikinolin származékok új enantiomerjei és szintézisük |
WO2020061476A1 (en) * | 2018-09-21 | 2020-03-26 | Jnana Therapeutics, Inc. | Small molecules targeting mutant mammalian proteins |
CN109797128A (zh) * | 2019-01-14 | 2019-05-24 | 浙江大学 | 一种急性细胞铁过载模型的构建方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7166448B1 (en) | 1999-05-10 | 2007-01-23 | Children's Medical Center Corproation | Ferroportin1 nucleic acids and proteins |
DE60231804D1 (de) | 2001-05-25 | 2009-05-14 | Inst Nat Sante Rech Med | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen |
US7749713B2 (en) | 2002-11-19 | 2010-07-06 | Hasan Kulaksiz | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor |
US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
US7723063B2 (en) | 2004-04-28 | 2010-05-25 | Intrinsic Lifesciences | Methods for measuring levels of bioactive human hepcidin |
CA2549477A1 (en) | 2005-06-29 | 2006-12-29 | The Regents Of The University Of California | Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin |
AU2007299629C1 (en) | 2006-09-21 | 2012-05-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the HAMP gene |
TW201206954A (en) | 2007-02-02 | 2012-02-16 | Amgen Inc | Hepcidin, hepcidin antagonists and methods of use |
CL2008000666A1 (es) | 2007-03-07 | 2008-06-13 | Xenon Pharmaceuticals Inc | Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro. |
AR065785A1 (es) | 2007-03-19 | 2009-07-01 | Xenon Pharmaceuticals Inc | Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro |
WO2008121861A2 (en) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
EP2068855A2 (en) | 2007-06-05 | 2009-06-17 | Xenon Pharmaceuticals Inc. | Aromatic and heteroaromatic compounds useful in treating iron disorders |
US20090053192A1 (en) | 2007-08-10 | 2009-02-26 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
GR1006896B (el) | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
US8487081B2 (en) | 2007-10-02 | 2013-07-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies specific for human hepcidin |
JO2828B1 (en) | 2007-11-02 | 2014-09-15 | ايلي ليلي اند كومباني | Anti-Hepsidine antibodies and their uses |
-
2010
- 2010-08-19 BR BR112012003701A patent/BR112012003701A2/pt not_active IP Right Cessation
- 2010-08-19 EP EP10743174A patent/EP2467361A1/de not_active Withdrawn
- 2010-08-19 AR ARP100103045A patent/AR077892A1/es unknown
- 2010-08-19 WO PCT/EP2010/062117 patent/WO2011020886A1/de active Application Filing
- 2010-08-19 CN CN2010800473240A patent/CN102574805A/zh active Pending
- 2010-08-19 US US13/390,785 patent/US20120196853A1/en not_active Abandoned
- 2010-08-19 JP JP2012525174A patent/JP2013502399A/ja not_active Withdrawn
- 2010-08-19 TW TW099127754A patent/TW201109324A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20120196853A1 (en) | 2012-08-02 |
TW201109324A (en) | 2011-03-16 |
BR112012003701A2 (pt) | 2019-09-24 |
JP2013502399A (ja) | 2013-01-24 |
WO2011020886A1 (de) | 2011-02-24 |
CN102574805A (zh) | 2012-07-11 |
EP2467361A1 (de) | 2012-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR077892A1 (es) | Quinolinas antagonistas de la hepcidina | |
AR077999A1 (es) | Antagonistas de pirimidin y triazin-hepcidina | |
AR085283A1 (es) | Antagonistas de hepcidina a base de sulfonaminoquinolina | |
DOP2011000237A (es) | Inhibidores de poli (adp-ribosa) polimerasa (parp) | |
UY33921A (es) | Oxazinopteridinas y oxazinoptiridinonas n-sustituidas | |
AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
SV2016005229A (es) | Inhibidores de syk | |
ECSP109903A (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
BR112013023876A2 (pt) | derivados de pirroltriazinona como inibidores de pi3k | |
TR201905814T4 (tr) | Jak inhibitörü olarak bipirazol tuzu. | |
EA201490912A1 (ru) | Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2 | |
AR078151A1 (es) | Conjugados de acidos grasos y niacina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades metabolicas. | |
UY30141A1 (es) | Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato | |
CR20120591A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
BR112015016395A2 (pt) | pirazóis 3-substituídos e uso como inibidores de dlk | |
PH12015500063B1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
BR112015007231A2 (pt) | derivados de pirroltriazinona como inibidores de pi3k | |
CR10356A (es) | Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3 | |
AR106652A1 (es) | Compuestos para tratar la esclerosis lateral amiotrófica | |
PE20151754A1 (es) | Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |